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Introduction
Second-trimester maternal serum screening for Down
syndrome using multiple biochemical markers was rou-
tinely carried out in Taiwan for several years [1]. Several
serum biochemical markers had been investigated for
Down syndrome screening. Nevertheless, human chori-
onic gonadotropin (hCG) has been the marker most
widely studied and applied for Down syndrome 
screening [2,3]. The molecular structure of hCG is com-
posed of two subunits, designated the α and β subunit.
Some commercially available kits are designed to meas-
ure the intact hCG plus its β subunit, the so-called total
hCG, but some sensitive kits are prepared to specifically
measure the β subunit as the free β-hCG. Measurement
of free β-hCG has been reported to improve the per-
formance of Down syndrome screening [4–8]. Although
the effectiveness of free β-hCG is controversial [9,10],
free β-hCG was recently advocated to be incorporated
in Down syndrome screening [3,6,8,11].
Since Asians account for a substantial proportion
of the world population, it is essential to judge which
markers should be included in a multiple-marker screen-
ing for Asians. Regarding the choice of serum markers,
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SUMMARY
Objective: The purpose of this study was to compare the effectiveness between total human chorionic
gonadotropin (hCG) and free β-hCG in two-marker Down syndrome screening programs during the second
trimester in a Taiwanese population.
Materials and Methods: From a multicenter collaborative study, we investigated the second-trimester maternal
serum levels of total hCG from 67 data, free β-hCG from 72 and alpha-fetoprotein (AFP) from 96 obtained
from Taiwanese pregnant women carrying fetuses with Down syndrome.
Results: High total hCG and free β-hCG, as well as low AFP levels, were found with median values of 2.06, 2.49
and 0.77 multiples of the median (MoM), respectively. At a 5% false-positive rate, total hCG and free β-hCG
could detect 31% and 43% of Down syndrome pregnancies, respectively, whilst AFP alone could detect only 15%
of affected cases. When combined with maternal age-specific risk, total hCG could achieve a 52% detection
rate, free β-hCG a 54% and AFP a 39%. Combined total hCG and AFP achieved a detection rate of 55%, and
combined free β-hCG and AFP achieved a rate of 60%.
Conclusion: The measurement of free β-hCG is more beneficial than total hCG in serum screening for Down
syndrome during the second trimester of pregnancy. [Taiwan J Obstet Gynecol 2007;46(3):230–235]
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alpha-fetoprotein (AFP) remains included as a marker
because of its widespread use in screening for neural
tube defects (NTDs). However, considering the cost-
benefit and controversy of unconjugated estriol (E3)
[12], we therefore adopted two-marker screening pro-
grams using AFP combining with either total hCG or
free β-hCG for Down syndrome screening in Taiwan.
There is a lack of data in the comparison of the effec-
tiveness between total hCG and free β-hCG in Asians.
In order to compare the effectiveness between total
hCG and free β-hCG, we had collected sizable data to
retrospectively evaluate the two-marker screening pro-
grams that used AFP combined with total hCG or free
β-hCG in a Taiwanese population.
Materials and Methods
There were 67 data of total hCG, 72 of free β-hCG and
96 of AFP maternal serum levels that were recorded
from a multicenter collaborative study of second-
trimester maternal serum screening for Down syn-
drome in Taiwan. Twenty-nine serum samples of total
hCG, 23 samples of free β-hCG, and 11 samples of
AFP were thawed and assayed after a storage time of
10.2 ± 2.7 months (range, 4.4–24.2 months), 7.2 ± 4.4
months (range, 0.3–20.9 months), and 9.1 ± 5.7
months (range, 3.1–20.9 months), respectively. Thirty-
eight sets of total hCG, 49 sets of free β-hCG and 86
sets of AFP data were collected from the collaborative
study of maternal serum screening for Down syn-
drome. As a suitable control population for compari-
son, we used the results from 10,925 unaffected
singleton pregnancies from routine serum screening
using total hCG that was designated as the total hCG
group, and 11,720 normal pregnancies using AFP and
free β-hCG were designated as the AFP and free β-hCG
groups, respectively. Information on the outcome of
the controls was obtained partly from karyotyping and
partly from information collected at delivery. None of
the affected and unaffected pregnancies was associated
with NTD or other congenital anomalies. Gestational
age in the total hCG group was determined by ultra-
sound in 80% of cases and by last menstrual period
(LMP) in 20% of cases; in the free β-hCG group, gesta-
tional age was determined by ultrasound in 82% of
cases and by LMP in 18% of cases.
AFP and total hCG were measured by a microparti-
cle enzyme immunoassay using the Abbott IMx auto-
analyzer (Abbott Laboratories, Abbott Park, IL, USA)
and free β-hCG was measured by a solid-phase, two-
site immunoradiometric assay (ELSA F-βHCG; CIS Ltd.,
Gif-sur-yvette Cedex, France). To correct for gestational
variation, results were converted to multiples of the
median (MoMs) for unaffected pregnancies at the re-
levant gestational age with our established weekly-
median values [13–15]. These analyte MoM levels were
corrected for maternal weight [16]. The maternal age-
specific risk was calculated from the formulae compiled
by Cuckle et al [17]. The Down syndrome risk was cal-
culated in combination with maternal age-specific risk
by using single marker in a univariate algorithm and
two markers in a bivariate algorithm [18].
Data analyses were accomplished using SPSS
Graduate Pack 8.0 (SPSS Inc., Chicago, IL, USA) for
Windows 95. We used the Kolmogorov-Smirnov test
to assess the normal Gaussian distributions of the ana-
lytes and Spearman’s or Pearson’s correlation coeffi-
cients to assess the correlation among these various
indices. A p value < 0.05 was considered statistically
significant. To compare the effectiveness of various
screening programs, regressed receiver operating char-
acteristic curves for each marker and in combination
were established by plotting the detection rate against
the respective false-positive rate.
Results
Maternal serum screening program in Taiwan was used
mainly for women under 35 years of age. Therefore,
only 5% (540/10,925) of the control population aged
35 years or older were in the total hCG group and 4%
(460/11,720) in the AFP and free β-hCG group versus
40 % (27/67), 36% (26/72), and 35% (34/96) in the
total hCG, free β-hCG and AFP group of Down syn-
drome pregnancies, respectively. This reflects that most
women carrying fetuses with Down syndrome were
referred for advancing maternal age. The mean and stan-
dard deviation (SD) of maternal age, weight, and ges-
tational age in the various groups of both normal and
Down syndrome pregnancies are shown in Table 1.
Serum total hCG, free β-hCG and AFP MoM values
for individual Down syndrome cases are shown in
Figure 1. It indicates that high total hCG and free β-hCG
levels, as well as low AFP level, are strongly associated
with Down syndrome pregnancies in Taiwanese. The
median value of total hCG in Down syndrome pregnan-
cies (n = 67) was 2.06 MoM (95% confidence interval
[CI], 1.82–2.25 MoM). The 10th and 90th centiles for
Down syndrome pregnancies were 1.07 and 4.08 MoM,
respectively, and those for the unaffected pregnancies
were 0.54 and 2.03 MoM, respectively. The median value
of free β-hCG in Down syndrome pregnancies (n = 72)
was 2.49 MoM (95% CI, 2.03–3.30 MoM). The 10th and
90th centiles for Down syndrome pregnancies were 0.82
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and 5.37 MoM, respectively, and those for the unaf-
fected pregnancies were 0.49 and 2.23 MoM, respec-
tively. The median value of AFP was 0.77 MoM (95%
CI, 0.72–0.84 MoM) in Down syndrome pregnancies
(n = 96). The 10th and 90th centiles for Down syndrome
pregnancies were 0.47 and 1.19 MoM, respectively, and
those for the unaffected pregnancies were 0.63 and
1.61 MoM, respectively.
Total hCG and AFP levels (n = 53) were shown to
have no correlation with maternal age in both affected
and unaffected pregnancies (total hCG: unaffected,
r = −0.003, p = 0.81; affected, r = 0.039, p = 0.79; and
AFP: unaffected, r = 0.018, p = 0.11; affected, r = 0.289,
p = 0.12). Free β-hCG and AFP (n = 72) were also shown
to have no correlation with maternal age in both af-
fected and unaffected pregnancies (β-hCG: unaffected,
r = −0.003, p = 0.81; affected, r = 0.039, p = 0.79; and
AFP: unaffected, r = 0.018, p = 0.11; affected, r = 0.289,
p = 0.12).
The distributions of the total hCG, free β-hCG and
AFP MoM values on log transformation in both affected
and unaffected pregnancies fitted a normal Gaussian
distribution (D = 0.516, p = 0.953; D = 0.831, p = 0.494;
D = 0.602, p = 0.862 for total hCG, free β-hCG, and
AFP, respectively, in Down syndrome pregnancies; and
D = 0.890, p = 0.407; D = 1.021, p = 0.061; D = 0.014,
p = 0.091 for total hCG, free β-hCG, and AFP, respec-
tively, in unaffected pregnancies) (Figure 2). Table 2
summarizes the statistics for the distribution of these
markers in affected and unaffected pregnancies. There
was no correlation between log total hCG and log AFP
distributions in affected pregnancies (r = 0.1707, p =
0.222), but correlation was found in unaffected preg-
nancies (r = 0.1120, p = 0.011). There was also no 
Table 1. Clinical characteristics of Down syndrome and unaffected pregnancies*
Down syndrome pregnancies Unaffected pregnancies
Total hCG Free β-hCG AFP Total hCG Free β-hCG AFP 
(n = 67) (n = 72) (n = 96) (n = 10,925) (n = 11,720) (n = 11,720)
Maternal age, yr 34.6 (4.7) 33.6 (4.5) 33.1 (5.8) 29.4 (3.3) 29.4 (3.5) 29.4 (3.5)
Maternal weight, kg 56.6 (5.9) 55.6 (6.9) 54.6 (9.3) 55.1 (5.1) 55.1 (7.5) 55.1 (7.5)
Gestational age, wk 17.9 (5.2) 18.3 (3.1) 17.8 (3.8) 17.2 (1.4) 16.8 (1.6) 16.8 (1.6)
*Data are presented as mean (standard deviation). hCG = human chorionic gonadotropin; AFP = alpha-fetoprotein.
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Figure 1. The distributions of AFP, total human chorionic
gonadotropin (hCG), and free β-hCG plotted as multiple of
the median (MoM) levels in Down syndrome pregnancies.
Solid lines in each group represent the median values of each
marker.
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Figure 2. Probability plots of the log multiple of the median
(MoM) values of alpha-fetoprotein (AFP), total human
chorionic gonadotropin (hCG), and free β-hCG for Down
syndrome pregnancies. The solid lines define the best fit for
the log Gaussian distribution.
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correlation between log free β-hCG and log AFP distri-
butions in affected (r = −0.0018, p = 0.988) and unaf-
fected pregnancies, (r = 0.0154, p = 0.096).
Free β-hCG is more discriminating than AFP or
total hCG alone. Free β-hCG would detect 31 of 72
(43%) Down syndrome cases, whilst total hCG alone
identified 21 of 67 (31%) affected cases at or above
the 95th centiles of the normal values (cut-off for free
β-hCG, 2.94 MoM; cut-off for total hCG, 2.43 MoM).
AFP alone could detect only 14 of 96 (15%) affected
cases at or be low the fifth centile of the normal values
(cut-off, 0.55 MoM). Table 3 shows the respective detec-
tion rates and false-positive rates at various risk cut-off
values. Significant improvements in the detection rates
were observed when serum markers were combined with
maternal age-related risk. Table 4 shows the Down
syndrome detection rates at a 5% false-positive rate of
each marker combining with maternal age in this study
and other previous studies.
Discussion
The use of hCG is unequivocally established in the
Down syndrome screening programs [2,3]. This study
confirms the observations of previous studies that ele-
vated total hCG level in maternal serum is associated
with Down syndrome pregnancies in whites [19,20]
and Asians [21]. The median values for affected preg-
nancies were 2.03 MoM (n = 90) in whites [6] and
2.05 MoM (n = 559) from the world literature [20],
compared with 2.06 MoM (n = 67) in this study of
Asians.
Eldar-Geva et al [22] showed that increased hCG
production in trisomy 21 trophoblasts was due to a
Table 2. Statistical parameters describing the distribu-
tion of each marker measured in Down syndrome and 
unaffected pregnancies
Affected Unaffected
Log mean
AFP −0.0971 0.0052
Total hCG 0.3198 0.0197
Free β-hCG 0.3634 0.0068
Log standard deviation
AFP 0.1952 0.1661
Total hCG 0.2112 0.2285
Free β-hCG 0.3020 0.2641
Correlation coefficient
Total hCG and AFP 0.1707 0.0032
Free β-hCG and AFP −0.0018 0.0154
AFP = alpha-fetoprotein; hCG = human chorionic gonadotropin.
Table 3. Detection rate (DR) and false-positive rate (FPR) at various risk cut-off levels for different combinations of 
serum markers and maternal age*
Risk cut-off level
190 250 270 300 350
DR FPR DR FPR DR FPR DR FPR DR FPR
AFP 23.7 1.9 35.1 3.0 36.1 3.6 38.1 4.4 42.3 6.0
Total hCG 50.7 4.7 56.7 6.7 58.2 7.3 59.7 8.5 61.2 10.0
Free β-hCG 56.9 4.7 56.9 6.2 59.7 6.6 63.9 7.4 68.1 8.6
Total hCG + AFP 55.2 4.1 59.7 5.7 61.2 6.3 64.2 6.9 67.2 8.5
Free β-hCG + AFP 58.3 4.7 62.5 6.2 65.3 6.7 69.4 7.4 72.2 8.8
*All values are in %. AFP = alpha-fetoprotein; hCG = human chorionic gonadotropin.
Table 4. Down syndrome detection rates at a 5% false-positive rate for combinations of various serum markers and 
maternal age
Present study Spencer et al [6] Wald et al [9] Knight et al [10]
AFP 39 27 36 –
Total hCG 52 45 49 44
Free β-hCG 54 54 48 37
Total hCG + AFP 55 45 58 58
Free β-hCG + AFP 60 59 57 50
AFP = alpha-fetoprotein; hCG = human chorionic gonadotropin.
marked increase in production of the β subunit. We
also found significantly elevated free β-hCG levels in
Down syndrome pregnancies of Asians, as were found
in white women. The median value for affected preg-
nancies in this study was 2.46 MoM (n = 72), which is
in agreement with those of whites, i.e. 2.36 MoM (n =
57) [23], and 2.41 MoM (n = 90) [6], but slightly lower
than our previous studies in Asians, i.e. 2.79 MoM (n =
47) [1], and whites, i.e. 2.64 MoM (n = 480) [24]. On
this basis of higher median values, free β-hCG should,
theoretically, be a better screening marker than total
hCG because of the greater separation of measurement
between affected and unaffected pregnancies.
This study also confirms the findings of previous
studies that lower serum AFP level is associated with
Down syndrome pregnancies. The median AFP value
of Down syndrome pregnancies (0.77 MoM) was in
agreement with those of whites (0.75 MoM) from the
world literature [9] and those of Asians (0.77 and
0.76 MoM) [1,8]. Our study confirms the observa-
tions of previous studies that poor performance was
achieved by AFP alone (≤ 0.5 MoM) screening strategy
[1,25,26], with a 13% detection rate at a 3% false-
positive rate. Although AFP contributes poorly in Down
syndrome screening, it remains as a component of
Down syndrome screening because of its role in NTD
screening.
Our study showed that second-trimester total hCG
levels in affected and unaffected cases in Asians fitted
a log Gaussian distribution that was similar to the dis-
tribution of the whites. The SD of the log MoM values
in affected and unaffected pregnancies in these studies
were, respectively, 0.283 and 0.241 [6], 0.252 and
0.224 [9], and 0.209 and 0.224 [10], compared with
a previous study of 0.326 and 0.231 [21] and our
present estimates of 0.211 and 0.229 in Asians.
In this study, second-trimester free β-hCG levels in
affected and unaffected cases in Asians also fitted a
log Gaussian distribution that was similar to the distri-
bution of the whites. The SD of the log MoM values in
affected and unaffected pregnancies in these studies
were, respectively, 0.301 and 0.294 [23], 0.332 and
0.254 [6], 0.317 and 0.256 of world literature (n =
454) [9], and 0.327 and 0.272 [10], compared with
our previous estimates of 0.322 and 0.261 [1] and the
present estimates of 0.302 and 0.264 in Asians. Although
the spread (log SD) of free β-hCG was slightly greater
in unaffected pregnancies than of the total hCG, the
greater spread of free β-hCG from affected pregnancies
may yield a better detection rate.
The second-trimester AFP levels in affected and
unaffected cases in Asians also fitted a log Gaussian
distributions that was similar to the distribution of the
whites. The SD of the log MoM values in affected and
unaffected pregnancies in these studies were 0.201 and
0.193 [6], 0.182 and 0.179 [9], and 0.151 and 0.147
[10], respectively, compared with our previous estimates
of 0.159 and 0.167 [1] and the present estimates of
0.195 and 0.166.
The differential production and clearance of free β-
hCG in Down syndrome pregnancies may account for
its better performance in the multiple-marker screening
test [22]. Our finding was similar to that of a previous
study in that free β-hCG was a more sensitive marker
than total hCG [6,11]. At a 5% false-positive rate,
Spencer et al [6] reported a 6% detection rate with
AFP, 39% with total hCG, and 47% with free β-hCG,
compared with our present estimates of 15% detection
rate with AFP, 31% with total hCG, and 43% with free
β-hCG. Table 4 shows that serum markers combined
with maternal age would increase the detection rate of
Down syndrome screening. However, this observed het-
erogeneity in screening performances may be caused
by differences in the methodology [10].
There is a trend of using free β-hCG instead of 
total hCG for Down syndrome screening in the United
Kingdom and Europe [3,27]. Although varying con-
clusions were reached about the free β-hCG, specific
measurement of free β-hCG can offer a further im-
provement in Down syndrome detection rate. It is not
only to gain better efficiency in the second trimester
screening [6,7,11] but also to achieve promising per-
formance in the first trimester serum screening in the
future [28,29]. In conclusion, measurement of free 
β-hCG in a two-marker screening program could be
beneficial in serum screening.
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